While the country hopes to start mass-producing the vaccine by October and plans to offer the first doses to essential workers, many in the science community seem unimpressed. The announcement should be taken "with a pinch of salt", said Indian immunologist Vineeta Bal.
Pharma major Dr. Reddy's Laboratories shut down its production facilities following a data breach in the servers, ET Now reported, citing sources.Data breach prompts Dr Reddy's to shut key plants
In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.
The vaccine has been developed by Siberia's Vector Institute, which completed early-stage human trials of the vaccine last month.
India's move comes as a setback for Russia's plan to roll-out the vaccine even before full trials show how well it works, while pushing back its efforts to win approval for the vaccine in the country that leads the world on average number of new infections.
Early in August, the Russians announced that they had successfully created a vaccine against the coronavirus, even as competitors remained in trial stages, with no products expected till 2021.